UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 401

Sortiert nach

Venetoclax in myeloma: to B, or not to B

Blood, 2024-01, Vol.143 (1), p.4

Raab, Marc S

2024

Volltextzugriff (PDF)

The Impact of Tumor Heterogeneity on Diagnostics and Novel Therapeutic Strategies in Multiple Myeloma

International journal of molecular sciences, 2019-03, Vol.20 (5), p.1248

2019

Volltextzugriff (PDF)

Multiple myeloma: patient outcomes in real‐world practice

British journal of haematology, 2016-10, Vol.175 (2), p.252-264

2016

Volltextzugriff (PDF)

Multiple myeloma

The Lancet (British edition), 2009-07, Vol.374 (9686), p.324-339

2009

Volltextzugriff (PDF)

Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma

The New England journal of medicine, 2018-11, Vol.379 (19), p.1811-1822

2018

Volltextzugriff (PDF)

Progression in Smoldering Myeloma Is Independently Determined by the Chromosomal Abnormalities del(17p), t(4;14), Gain 1q, Hyperdiploidy, and Tumor Load

Journal of clinical oncology, 2013-12, Vol.31 (34), p.4325-4332

2013

Volltextzugriff (PDF)

Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes

Blood, 2016-09, Vol.128 (9), p.1226-1233

2016

Volltextzugriff (PDF)

Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single-cell transcriptomics

Nature communications, 2021-11, Vol.12 (1), p.6960-6960, Article 6960

2021

Volltextzugriff (PDF)

Multiple myeloma: practice patterns across Europe

British journal of haematology, 2016-10, Vol.175 (1), p.66-76

2016

Volltextzugriff (PDF)

Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patients

Haematologica (Roma), 2021-10, Vol.106 (10), p.2754

2021

Volltextzugriff (PDF)

A precision‐based exercise program for patients with multiple myeloma

European journal of haematology, 2023-12, Vol.111 (6), p.930-937

2023

Volltextzugriff (PDF)

Impact of Clonal Heterogeneity in Multiple Myeloma

Hematology/oncology clinics of North America, 2024-04, Vol.38 (2), p.461-476

2024

Volltextzugriff (PDF)

Targeting the BRAF V600E mutation in multiple myeloma

Cancer discovery, 2013-08, Vol.3 (8), p.862-869

2013

Volltextzugriff (PDF)

Reproducible Radiomics Features from Multi-MRI-Scanner Test-Retest-Study: Influence on Performance and Generalizability of Models

Journal of magnetic resonance imaging, 2024-05

2024

Volltextzugriff (PDF)

Oxygen bubbles to predict sensitivity to IMiDs

Blood, 2017-02, Vol.129 (8), p.923-925

Raab, Marc S.

2017

Volltextzugriff (PDF)

Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial

Journal of clinical oncology, 2023-01, Vol.41 (3), p.568-578

2023

Volltextzugriff (PDF)

Whole‐body magnetic resonance imaging plus serological follow‐up for early identification of progression in smouldering myeloma patients to prevent development of end‐organ damage

British journal of haematology, 2022-10, Vol.199 (1), p.65-75

2022

Volltextzugriff (PDF)

First‐line therapy with bendamustine/prednisone/bortezomib—A GMMG trial for non‐transplant eligible symptomatic multiple myeloma patients

European journal of haematology, 2020-08, Vol.105 (2), p.116-125

2020

Volltextzugriff (PDF)

The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients

Cancer cell, 2023-04, Vol.41 (4), p.711-725.e6

2023

Volltextzugriff (PDF)

Spatially divergent clonal evolution in multiple myeloma: overcoming resistance to BRAF inhibition

Blood, 2016-04, Vol.127 (17), p.2155-2157

2016

Volltextzugriff (PDF)

STIL is required for centriole duplication in human cells

Journal of cell science, 2012-03, Vol.125 (Pt 5), p.1353-1362

2012

Volltextzugriff (PDF)

Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trials

BMC cancer, 2023-11, Vol.23 (1), p.1-1132, Article 1132

2023

Volltextzugriff (PDF)

Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma

Journal of clinical oncology, 2024-01, Vol.42 (1), p.26

2024

Volltextzugriff (PDF)

1 – 25 von 401

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(382)
Mit Volltextzugriff
(379)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Venetoclax in myeloma: to B, or not to B

The Impact of Tumor Heterogeneity on Diagnostics and Novel Therapeutic Strategies in Multiple Myeloma

Multiple myeloma: patient outcomes in real‐world practice

Multiple myeloma

Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma

Progression in Smoldering Myeloma Is Independently Determined by the Chromosomal Abnormalities del(17p), t(4;14), Gain 1q, Hyperdiploidy, and Tumor Load

Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes

Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single-cell transcriptomics

Multiple myeloma: practice patterns across Europe

Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patients

A precision‐based exercise program for patients with multiple myeloma

Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results

Impact of Clonal Heterogeneity in Multiple Myeloma

Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE

Targeting the BRAF V600E mutation in multiple myeloma

Reproducible Radiomics Features from Multi-MRI-Scanner Test-Retest-Study: Influence on Performance and Generalizability of Models

Oxygen bubbles to predict sensitivity to IMiDs

Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial

Whole‐body magnetic resonance imaging plus serological follow‐up for early identification of progression in smouldering myeloma patients to prevent development of end‐organ damage

First‐line therapy with bendamustine/prednisone/bortezomib—A GMMG trial for non‐transplant eligible symptomatic multiple myeloma patients

The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients

Spatially divergent clonal evolution in multiple myeloma: overcoming resistance to BRAF inhibition

STIL is required for centriole duplication in human cells

Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trials

Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma

Suchergebnisse filtern